The initial screening involves confirming eligibility based on age, weight, and a diagnosis of eosinophilic esophagitis (EoE).

Participants must have a history of at least two episodes of difficulty swallowing per week in the four weeks prior to the screening.

A stable diet and medication regimen must be maintained for at least eight weeks before the screening.

Baseline assessments include measuring the severity of symptoms and conducting an esophageal biopsy to confirm the presence of EoE.

Participants may continue their current medications for EoE, such as proton pump inhibitors (PPI) or swallowed topical corticosteroids (STC), as long as these have been stable for at least eight weeks.

Participants are randomly assigned to receive either tezepelumab or a placebo.

The treatment involves a subcutaneous injection of Tezspire 210 mg solution, administered at regular intervals.

The treatment period lasts for 24 weeks, during which participants receive regular injections.

Participants are monitored for changes in symptoms and esophageal histology.

At week 24, an evaluation is conducted to assess the histologic response and symptom improvement.

The primary goal is to achieve a reduction in eosinophil count in the esophagus and improvement in swallowing difficulties.

Participants continue treatment for an additional 28 weeks, totaling 52 weeks of treatment.

Further assessments are conducted to monitor long-term effects and safety.

At week 52, a final evaluation is performed to measure the overall effectiveness of the treatment.

This includes assessing changes in eosinophil count, symptom scores, and any potential side effects.